Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome wide CRISPR screen for BET inhibitor resisatnce in OCI-AML2 cells using Y. Kosuke library

ABSTRACT: OCI-AML2 BETi-naive or JQ1 resistant cells were infected with CRISPR/Cas9 library, selected for puromycin resistance for integration events and exposed to JQ1/CPI-0610 or vehicle, DMSO, at 200nanoMolar for JQ1 and 500nanoMolar CPI-0610 concentrations. Cells were collected at time 0 (post puromycin selection), day 14 JQ1 and 21 CPI-0610 , DNA was extracted and sgRNA barcodes were amplified. PCR library was deep sequenced using highthroughput Illumina platform Hiseq using 6 samples per lane.

ORGANISM(S): Homo sapiens

PROVIDER: GSE159689 | GEO | 2023/10/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Genome wide CRISPR screen for CG-806 resistance in OCI-LY3 cells using Y. Kosuke library

Project description:OCI-LY3 cells were infected with CRISPR/Cas9 library, selected for puromycin resistance for integration events and exposed to CG-806 or vehicle, DMSO, at 1 microMolar concentrations. Cells were collected at time 0 (post puromycin selection) and day 7. DNA was extracted and sgRNA barcodes were amplified. PCR library was deep sequenced using highthroughput Illumina platform Novaseq 6000.

2023-05-04 | GSE174766 | GEO

Genome wide CRISPR screen for Venetoclax plus Ruxolitinib combination resistance in OCI-AML2 cells using Y. Kosuke library

Project description:30 million OCI-AML2 cells were infected with CRISPR/Cas9 library, selected for puromycin resistance for integration events and exposed DMSO, venetoclax (0.5 uM) or venetoclax (0.1 uM) plus ruxolitinib (1 uM). Cells were collected at day 14 and 21 , DNA was extracted and sgRNA barcodes were amplified. PCR library was deep sequenced using Novaseq 6000 high throughput Illumina platform.

2023-06-30 | GSE216087 | GEO

Genome wide CRISPR screen for Venetoclax resisatnce in MOLM13 cells using Y. Kosuke library

Project description:MOLM13 cells were infected with CRISPR/Cas9 library, selected for puromycn resistance for integration events and exposed to Venetoclax or vehicle, DMSO, at 1microMolar concentrations. Cells were collected at time 0 (post puromycin selection), day 7 and 14 , DNA was extracted and sgRNA barcodes were amplified. PCR library was deep sequenced using highthroughput Illumina platform Hiseq using 6 samples per lane.

2019-04-30 | GSE130412 | GEO

RNA-seq expression profiling of OCI-AML2 and OCI-AML3 cells upon CRISPR/Cas9 –mediated disruption of DDX3X RNA binding domain

Project description:Human acute myeloid leukemia cell lines OCI-AML2 and OCI-AML3 were used in a CRISPR/Cas9-mediated approach to specifically target DDX3X’s gene sequences encoding the RNA binding domain of the helicase. DDX3X RNA binding domain is bipartite in the two halves of the helicase core. sgRNAs were designed to target both halves of the domain (named RNA binding domain A and B – RBDA and RBDB). We performed RNA-seq to observe the gene expression changes in both OCI-AML2 and OCI-AML3 cell lines following the not-combined CRISPR/Cas9 –mediated targeting of both regions of the DDX3X RNA binding domain. Control CRISPR/Cas9 performed with no sgRNA expressing vector (named “empty vector”) was performed in both cell lines. The latter condition was used as a control for gene expression changes analysis, for each cell line.

2019-11-23 | E-MTAB-6241 | biostudies-arrayexpress

Transcription profiling of human acute myeloid leukemia cell line OCI/AML2 with the anti-parasitic ivermectin

Project description:OCI AML2 cells were treated with the anti-parasitic ivermectin (single dose, two time points) in order to assess gene expression changes.

2010-01-06 | E-MEXP-2528 | biostudies-arrayexpress

Epigenome analysis of parental and ABT-199 resistant AML cell lines

Project description:Genome wide DNA methylation profiling of parental, ABT-199 resistant population, and ABT-199 resistant clones from 3 acute myelogenous leukemia (AML) cell lines (MOLM-13, MV-4-11, OCI-AMLO2). The Illumina Infinium MethylationEPIC Human DNA methylation Beadchip was used to obtain DNA methylation profiles across approximately 850,000 CpGs from AML cell line samples. Samples include 4 ABT-199 sensitive parental MOLM-13 population samples, 4 ABT-199 resistant MOLM-13 population samples, 3 ABT-199 resistant MOLM-13 S2 clone samples, 3 ABT-199 resistant MOLM-13 S5 clone samples, 4 ABT-199 resistant MOLM-13 S6 clone samples, 3 ABT-199 sensitive parental MV-4-11 population samples, 3 ABT-199 resistant MV-4-11 population samples, 3 ABT-199 sensitive parental OCI-AML2 population samples, 3 ABT-199 resistant OCI-AML2 population samples, 3 ABT-199 resistant OCI-AML2 S1 clone samples, 3 ABT-199 resistant OCI-AML2 S2 clone samples, 3 ABT-199 resistant OCI-AML2 S8 clone samples.

2022-01-12 | GSE193254 | GEO

Genome wide CRISPR screen for Sorafenib resistance in MOLM13 and MV411 cells using Y. Kosuke library

Project description:MOLM13 or MV411 cells were generated to express Cas9, infected with CRISPR library (Tzelepis et al 2016) , selected for puromycin resistance and exposed to Sorafenib (50nM), Crenolanib (20nM) or vehicle, DMSO. Cells were collected at time 0 (post puromycin selection), day 7 and 14 for Sorafenib as well as 14 and 21 for Crenolanib. DNA was extracted and sgRNA barcodes were amplified. The resulting PCR library was deep sequenced using the Illumina HiSeq 2500 using 6 samples per lane.

2021-05-19 | GSE138343 | GEO

Gene expression profiling of AML cell lines treated with nuclear export inhibitor, selinexor

Project description:RNA-seq analysis in OCI-AML2 and MOLM-13 cells treated with selinexor or DMSO for 36 hours.

2022-01-01 | GSE181003 | GEO

Genome wide CRISPR screen for Venetoclax resisatnce in MOLM13 cells using Brunello library

2019-04-30 | GSE130413 | GEO

Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant I

Project description:Global gene expression profiling was performed on OCI-AML2 leukemia cell line, R3 and R50 drug resistant cell lines.

2020-08-28 | GSE108142 | GEO